来自治疗剂量的电离辐射的反向散射不会损害植入物上的细胞迁移 in vitro
Lisa Printzell1, Janne Elin Reseland2, Nina Frederike Jeppesen Edin3
1Department of Prosthodontics, Institute of Clinical Dentistry, Faculty for Dentistry, University of Oslo, PO box 1109, 0317, Blindern, Oslo, Norway. lisa.printzell@odont.uio.no.
Clinical oral investigations
|July 6, 2023
概括
的辐射反射增加了人体细胞中的DNA损伤. 高剂量的辐射抑制了上的细胞迁移,但传统的放射治疗剂量似乎对牙植入物骨质整合是安全的.
科学领域:
- 生物材料科学 生物材料科学
- 细胞生物学 细胞生物学
- 放射治疗研究 放射治疗研究
背景情况:
- 牙植入物通常在放射治疗前进行,因此需要了解如何与辐射相互作用.
- 来自的辐射反射可以影响骨质整合至关重要的细胞的生物反应,例如骨质母细胞 (OBs) 和介质干细胞 (MSCs).
- 评估即时的DNA损伤和细胞迁移对于预测放射治疗后的植入成功至关重要.
研究的目的:
- 调查辐射反射对人类OB和MSCDNA损伤和迁移能力的影响.
- 为了比较电离辐射对培养细胞和塑料培养细胞的影响.
- 评估与放射治疗之前放置的牙科植入物相关的潜在风险.
主要方法:
- 人类的OB和MSC是在加工的,化物修饰的或聚烯上培养的.
- 细胞暴露于不同剂量的电离辐射 (2,6,10,14 Gy).
- 在辐射后立即使用彗星试验评估DNA损伤,并在辐射后24小时通过伤愈合试验评估迁移能力,并使用活细胞成像.
主要成果:
- 随着辐射剂量的增加,DNA损伤升级,并被反散放大,MSC比OB更敏感.
- 虽然所有辐射剂量都加速了塑料上的细胞迁移,但对于两种细胞类型,只有最高剂量 (10 Gy) 抑制了上的细胞迁移.
- 较低的辐射剂量 (2和6 Gy) 并没有显著影响OB或MSC在上的迁移.
结论:
- 高剂量的辐射 (10 Gy) 显著抑制了OB和MSC在表面的迁移.
- 传统的分离放射治疗剂量 (例如,每天2Gy) 似乎不会导致严重的DNA损伤或阻碍骨整合所需的迁移.
- 这些发现表明,植入物可以在传统放射治疗之前安全地集成,只要剂量水平得到控制.
相关概念视频
01:16Methods for Studying Drug Absorption: In vitro
In vitro experiments are crucial for understanding the transport and absorption of drugs through biological materials. These studies employ varied methods such as the diffusion cell method, the everted sac technique, and the everted ring technique.
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...